<prompt> Erenumab was approved by FDA in 2018 forPhenylketonuriaMigraineHypeensionGlycogen storage disorders  <response>: Erenumab belongs to a new class of drugs known as selective calcitonin gene-related peptide CGRP antagonists, which are used for the treatment of acute migraine attacks. 